The Global Life Science Reagents Market Size accounted for USD 55.3 Billion in 2023 and is estimated to achieve a market size of USD 92.2 Billion by 2032 growing at a CAGR of 5.9% from 2024 to 2032.
The life science reagents market is experiencing significant advancements, driven by technological innovations and the integration of automation. Two trending long-tail LSI (Latent Semantic Indexing) keywords in this domain are "automation in urinalysis testing" and "molecular diagnostics for infectious diseases." This article explores these topics through pertinent questions, highlighting recent developments and the contributions of leading companies in the field.
Request a free sample of our research report @ https://www.acumenresearchandconsulting.com/request-sample/1464
How Is Automation Enhancing Urinalysis Testing?
Automation is revolutionizing urinalysis testing by improving accuracy, efficiency, and standardization. Traditional manual methods are prone to variability and errors, whereas automated systems offer consistent and reliable results. Automated urine analyzers, especially beneficial for high-workload laboratories, can simultaneously perform microscopic analysis for a large number of samples, thereby improving turnaround time. For instance, in September 2021, Beckman Coulter unveiled the DxU Iris Workcell, a revolutionary urinalysis solution that reduces sample processing time.
Sysmex Corporation has also been at the forefront of integrating automation into urinalysis. Their systems standardize processes, minimize human involvement, and enhance data management, leading to improved quality and reduced turnaround times. These advancements underscore the critical role of automation in modern urinalysis testing.
What Are the Latest Innovations in Molecular Diagnostics for Infectious Diseases?
Molecular diagnostics have become pivotal in the rapid and accurate detection of infectious diseases. The global molecular diagnostics market for infectious diseases is projected to reach approximately $17.61 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030.
This growth is driven by technological advancements and the increasing prevalence of infectious diseases.
Leading companies are making significant strides in this area:
DiaSorin SpA: In July 2021, DiaSorin acquired Luminex, gaining access to multiplexing technology and a portfolio that strengthens its existing offerings. This acquisition enhances DiaSorin's presence in the U.S. and supports academic and scientific research, expanding engagement with biopharma companies.
F. Hoffmann-La Roche Ltd.: In June 2023, Roche received FDA clearance for an updated molecular test for COVID-19, designed to reduce false positives and implement an error flag for invalidated samples. The RT-PCR-based Cobas SARS-CoV-2 Qualitative test is used with nasal and nasopharyngeal specimens from patients with suspected COVID-19 and is designed for use on the Cobas 5800, 6800, and 8800 instruments.
Thermo Fisher Scientific Inc.: In June 2023, Thermo Fisher secured FDA clearance for its Sensititre 20- to 24-Hour Haemophilus influenzae/Streptococcus pneumoniae MIC or breakpoint susceptibility system. This system is intended for clinical susceptibility testing of fastidious isolates, specifically for imipenem-relebactam (Merck's Recarbrio) in a specific dilution range for testing fastidious H. influenzae.
Becton Dickinson and Company (BD): In June 2023, BD received FDA clearance for a semi-quantitative agar diffusion test to determine the susceptibility of certain Gram-positive and Gram-negative bacteria to the antimicrobial lefamulin (Nabriva Therapeutics' Xenleta). The BD BBL Sensi-Disc Lefamulin 20 μg is used to determine the susceptibility of S. pneumoniae, Staphylococcus aureus, and H. influenzae.
bioMérieux SA: In April 2018, bioMérieux acquired Astute Medical Inc., reinforcing its offering of high medical value immunoassay biomarkers. Astute developed the Nephrocheck test, an FDA-cleared test for the early risk assessment of acute kidney injuries based on the level of two biomarkers, IGFBP-7 and TIMP-2. This acquisition enhances bioMérieux's portfolio in the immunoassay market.
These innovations highlight the dynamic nature of molecular diagnostics in combating infectious diseases. The integration of advanced technologies facilitates early detection, enabling timely interventions and improved patient outcomes.
Request a Customized Copy of Report @ https://www.acumenresearchandconsulting.com/request-customization/1464
How Are Leading Companies Integrating New Technologies in Life Science Reagents?
Several key companies are pioneering the integration of new technologies in life science reagents:
Becton Dickinson and Company (BD): In July 2018, BD released the BD AbSeq assay, enabling protein expression analysis at the single-cell level using high-throughput sequencing. This innovation allows researchers to simultaneously analyze RNA and proteins in thousands of individual cells, providing a comprehensive understanding of biological systems.
bioMérieux SA: In November 2018, bioMérieux acquired a majority stake in Suzhou Hybiome Biomedical Engineering Co. Ltd., a company specializing in automated immunoassay tests. This acquisition strengthens bioMérieux's presence in the immunoassay market and enhances its diagnostic solutions portfolio.
Siemens Healthineers: In June 2023, Siemens received FDA clearance for three assays, including an automated immunoturbidimetric assay for the quantitative determination of the von Willebrand antigen in human plasma. These assays are designed for use on advanced analyzers, enhancing diagnostic capabilities.
Other Tranding Report :
US Cannabis Sifting & Accessory Market
Medical Affairs Outsourcing Market Hit US$ 2.65 Bn by 2026
Viral Vector and Plasmid DNA Manufacturing Market 2020-2026
Prosthetics and Orthotics Market Size US$ 12.5 Bn by 2026
Transplant Diagnostics Market Size, Share, Growth, Scope 2027
Herceptin Biosimilar Market Size, Share, Trends | Forecast 2026 (Section Purchase)
Red Biotechnology Market, 2019 - 2026
About Acumen Research:
At Acumen Research, we collaborate with a diverse network of alliance publishers, enabling us to deliver precise and tailored market insights across various industry verticals. Our deep understanding of market dynamics allows us to effectively address client requirements, identify emerging opportunities, and recommend the most relevant research solutions.
With an extensive portfolio of in-depth research reports, our comprehensive database covers a wide range of market categories and sub-categories. We are committed to providing businesses with actionable intelligence, empowering them to make informed decisions and stay ahead in an ever-evolving marketplace.
For Latest Update Follow Us on Twitter and, LinkedIn
Contact Us:
Mr. Richard Johnson
India: +918983225533
E-mail::[email protected]